Streetbeat News

Equity Actions

ERAS

Erasca's stock price increased following the announcement of a $45 million private placement financing.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 1:03 pm

EHC

Encompass Health (NYSE:EHC) has received mixed analyst ratings over the past three months, with 6 analysts offering evaluations. The sentiment has shifted slightly positive, with the average 12-month price target rising to $88.67 from $84.67. Analysts from Barclays, Truist Securities, RBC Capital, Mizuho, and Stephens & Co. have provided updates, with actions including raising and maintaining ratings, and adjusting price targets. Encompass Health's financial performance shows strong market position, revenue growth, profitability, and effective asset utilization, despite facing challenges in achieving growth rates higher than the average in the Health Care sector.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 1:00 pm

AZTA

Analysts have diverse opinions on Azenta (NASDAQ:AZTA), with recent evaluations showing a mix of bullish and indifferent stances. Over the last three months, 7 analysts provided ratings, with the majority being bullish. The average 12-month price target for AZTA has been raised to $75.00 from $70.00, indicating a positive outlook. Azenta's financial performance shows challenges in revenue growth and return metrics, but efficient cost management and prudent debt strategy are noted positives.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 1:00 pm

OMC

In the last three months, 5 analysts have updated their ratings on Omnicom Group (NYSE:OMC), showing a mix of bullish and indifferent stances. The average 12-month price target has risen to $104.6, marking a 20.69% increase from the previous target. Analysts from firms like Exane BNP Paribas, Wells Fargo, Barclays, UBS, and Macquarie have adjusted their ratings and price targets, reflecting a positive outlook on OMC's performance. Omnicom's financials show strong revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 1:00 pm

NKE

SN

SharkNinja Inc (NYSE:SN) has appointed Patraic Reagan, a former Nike Inc. (NYSE:NKE) executive, as its new CFO effective April 22, 2024. Reagan's experience includes serving as CFO for Nike's Asia, Pacific, and Latin America segment. Larry Flynn, the Interim CFO since June 2023, will resume his role as Chief Accounting Officer. SharkNinja's shares closed higher by 3.37% at $62.94 following the announcement.

Portfolio Pulse from Shivani Kumaresan

March 28, 2024 | 12:56 pm

AMC

AMC Entertainment has initiated an equity distribution agreement to periodically sell shares totaling $250,000,000 through an 'at-the-market' program, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:52 pm

BLK

NKLA

NVDA

TSLA

The crypto market cap surpasses $2.6 trillion, driven by Dogecoin's spike and BlackRock's successful Bitcoin ETF. In US markets, Nvidia is removed from Piper Sandler's model portfolio, and the S&P 500 hits a new record. Biden's comprehensive policy for federal AI use is unveiled, amid various political and economic developments globally. In tech, significant investments in AI and lithium signal industry confidence. The electric vehicle sector sees mixed fortunes, with Tesla adjusting to Mexico's EV charging rules and Nikola launching a hydrogen fueling station.

Portfolio Pulse from Akanksha Bakshi

March 28, 2024 | 12:49 pm

CRVO

CervoMed's stock price has increased following the announcement of a private placement financing. This move is likely to provide the company with additional capital, potentially boosting its operations and growth prospects.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:48 pm

AVTX

BDRX

XLO

Avalo Therapeutics (AVTX) saw a 406% increase after acquiring an Anti-IL-1β mAb and announcing a private placement financing of up to $185 million. Xilio Therapeutics (XLO) experienced a 399% surge following an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program and a $11.3 million private placement equity financing. Biodexa (BDRX) shares rose by 46% as its MTX110 showed promise in extending life expectancy against aggressive brain cancers.

Portfolio Pulse from ryanfaloona@benzinga.com

March 28, 2024 | 12:36 pm

AMZN

BOTZ

GOOG

GOOGL

META

MSFT

NVDA

SMH

Nvidia Corp dominates the data center GPU market with a 92% share, highlighting U.S. leadership in generative AI. The company's CUDA platform is widely used by developers, contributing to its market value surge to $1.73 trillion by 2024. U.S. tech giants like Meta Platforms, Amazon, Microsoft, and Alphabet lead in cloud infrastructure and AI investments. Nvidia's sales from data centers are expected to constitute over 85% of its total revenue. The stock has surged 242% in the last 12 months, with exposure available through VanEck Semiconductor ETF and Global X Robotics & Artificial Intelligence ETF.

Portfolio Pulse from Anusuya Lahiri

March 28, 2024 | 12:35 pm